Ascentage Pharma Group International (HKSE:06855) Growth Rank : 4 (As of Jun. 23, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Ascentage Pharma Group International Growth Rank?

Ascentage Pharma Group International has the Growth Rank of 4.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Competitive Comparison of Ascentage Pharma Group International's Growth Rank

For the Biotechnology subindustry, Ascentage Pharma Group International's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascentage Pharma Group International's Growth Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's Growth Rank distribution charts can be found below:

* The bar in red indicates where Ascentage Pharma Group International's Growth Rank falls into.

Ascentage Pharma Group International Growth Rank Related Terms

Thank you for viewing the detailed overview of Ascentage Pharma Group International's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascentage Pharma Group International (HKSE:06855) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascentage Pharma Group International (HKSE:06855) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

ASPHF:USA 36X:Germany

Address

68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000

Website

https://www.ascentagepharma.com

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company's geographical segments include the United States and Mainland China.

Executives

Ascentage Limited
Gao Sharon Xia
Guo Edward Ming
Healthquest Pharma Limited
Li Ju-yun
Wang Shaomeng
Yang Dajun
Zhai Yifan
South Dakota Trust Company Llc	2301 Trustee
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Tian Yuan	2201 Interest of corporation controlled by you
Zhao Li	2202 Interest of your spouse
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin You Xian He Huo	2201 Interest of corporation controlled by you
Xian Jin Zhi Zao Chan Ye Tou Zi You Xian Gong Si	2101 Beneficial owner
Guo Tou Chuang Xin Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you

Ascentage Pharma Group International (HKSE:06855) Headlines

No Headlines